Results 1 to 10 of about 830,578 (209)

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]

Nature Communications
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium   +24 more
doaj   +3 more sources

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers [PDF]

BMC Infectious Diseases
Background Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited.
Suwarti Suwarti, Gilbert Lazarus, Sabighoh Zanjabila, Robert Sinto, Fransiska Fransiska, Theresia Deborah, Dwi Oktavia, Junaidah Junaidah, Santayana Santayana, Henry Surendra, Jeng Yuliana, Herlina Pardosi, Nunung Nuraeni, Saraswati Soebianto, Novi Dwi Susilowati, Decy Subekti, Ariel Pradipta, J. Kevin Baird, Le Van Tan, Susanna Dunachie, Anuraj H. Shankar, Erni J. Nelwan, Raph L. Hamers, SEACOVARIANTS Consortium   +23 more
doaj   +4 more sources

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters [PDF]

Frontiers in Immunology
BackgroundCharacterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines.MethodsThis study ...
Bethany Girard, Elisabeth Baum-Jones, Rebecca L. Best, Thomas W. Campbell, Jack Coupart, Kyla Dangerfield, Abhilash Dhal, Michael Jhatro, Brian Martinez, Jack Reifert, John Shon, Minlu Zhang, Rebecca Waitz, Spyros Chalkias, Darin K. Edwards, Maha Maglinao, Robert Paris, Rolando Pajon   +17 more
doaj   +5 more sources

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. [PDF]

PLoS Medicine, 2022
BackgroundMyocarditis and pericarditis following the Coronavirus Disease 2019 (COVID-19) mRNA vaccines administration have been reported, but their frequency is still uncertain in the younger population.
Marco Massari, Stefania Spila Alegiani, Cristina Morciano, Matteo Spuri, Pasquale Marchione, Patrizia Felicetti, Valeria Belleudi, Francesca Romana Poggi, Marco Lazzeretti, Michele Ercolanoni, Elena Clagnan, Emanuela Bovo, Gianluca Trifirò, Ugo Moretti, Giuseppe Monaco, Olivia Leoni, Roberto Da Cas, Fiorella Petronzelli, Loriana Tartaglia, Nadia Mores, Giovanna Zanoni, Paola Rossi, Sarah Samez, Cristina Zappetti, Anna Rosa Marra, Francesca Menniti Ippolito, TheShinISS-Vax|COVID Surveillance Group   +26 more
doaj   +2 more sources

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP [PDF]

British medical journal, 2023
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Design Matched cohort study, emulating a comparative effectiveness trial.
Andrews, Colm D, Bacon, Sebastian CJ, Curtis, Helen J, Goldacre, Ben, Hernán, Miguel A, Horne, Elsie MF, Hulme, William J, Keogh, Ruth H, MacKenna, Brian, Mehrkar-Asl, Amir, Morley, Jessica, Palmer, Tom M, Parker, Edward PK, Sterne, Jonathan AC, Walker, Alex J, Walker, Venexia, Williamson, Elizabeth J   +16 more
core   +6 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase [PDF]

New England Journal of Medicine, 2021
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Anderson, EJ, August, A, Babiker, A, Baden, LR, Bruno, R, Campbell, TB, Clark, J, Clouting, H, Cooper, LA, Corey, L, Deng, W, Doblecki-Lewis, S, Eder, F, El Sahly, HM, Ellenberg, SS, Essink, B, Faugno, A, Feldman, G, Fichtenbaum, CJ, Fix, A, Follmann, D, Gilbert, P, Gorman, R, Graham, BS, Griffin, M, Hamill, RJ, Hamilton, H, Han, S, Han-Conrad, L, Horwith, G, Huynh, C, Jackson, LA, Janes, H, Joffe, S, Kalil, J, Kennelly, C, Leav, B, Ledgerwood, JE, Levin, M, Levine, MM, Lipsitz, L, Makgoba, MW, Manzo, D, Marovich, M, Martin, JM, Mascola, JR, Miller, J, Moore, RH, Mytle, N, Neuzil, KM, Pajon, R, Pavetto, C, Polakowski, L, Rankin, B, Rosenberg, ES, Schödel, F, Tomassini, JE, Tong, X, Treanor, J, Tsiatis, AA, Whitley, RJ, Zervos, M, Zhou, H   +62 more
core   +2 more sources

Breakhthrough Infection Pasca Pemberian Booster mRNA Heterolog pada Tenaga Kesehatan di RSUD Arifin Achmad [PDF]

Majalah Kedokteran Andalas, 2023
Tujuan: Mengetahui prevalensi dan karakteristik responden breakthrough infection pada tenaga kesehatan di RSUD Arifin Achmad Provinsi Riau dalam 14 hari – 6 bulan pasca vaksinasi booster mRNA-1273. Metode: Metode penelitian cross sectional yang dilakukan
Dina Br Nababan, Eka Bebasari, Ligat Pribadi Sembiring, Dani Rosdiana, Rahmat Azhari Kemal   +4 more
doaj   +3 more sources

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study [PDF]

British medical journal, 2021
Objective To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death). Design Test negative design study.
Hannah Chung, Siyi He, Sharifa Nasreen, Maria E. Sundaram, Sarah A. Buchan, Sarah E. Wilson, Branson Chen, Andrew Calzavara, Deshayne B. Fell, Peter C. Austin, Kumanan Wilson, Kevin L. Schwartz, Kevin A. Brown, Jonathan B. Gubbay, Nicole E. Basta, Salaheddin M. Mahmud, Christiaan H. Righolt, Lawrence W. Svenson, Shannon E. MacDonald, Naveed Z. Janjua, Mina Tadrous, Jeffrey C. Kwong   +21 more
openalex   +2 more sources

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Science, 2021
Description A smaller-dose jab does the job Low-dose messenger RNA (mRNA) vaccines potentially allow health providers to administer more doses from a limited vaccine supply and can be less reactogenic.
José Mateus, Jennifer M. Dan, Zeli Zhang, Carolyn Rydyznski Moderbacher, Marshall Lammers, Benjamin Goodwin, Alessandro Sette, Shane Crotty, Daniela Weiskopf   +8 more
openalex   +2 more sources

mRNA-1273 is placenta-permeable and immunogenic in the fetus [PDF]

Molecular Therapy: Nucleic Acids
COVID-19 mRNA vaccines are generally recognized as safe for gestational administration. However, their transplacental pharmacokinetics remain obscure. In this study, mRNA-1273 intramuscularly given to pregnant mice rapidly circulated in maternal blood ...
Jeng-Chang Chen, Mei-Hua Hsu, Rei-Lin Kuo, Li-Ting Wang, Ming-Ling Kuo, Li-Yun Tseng, Hsueh-Ling Chang, Cheng-Hsun Chiu   +7 more
doaj   +2 more sources